TRGM — Targeted Medical Pharma Share Price
Last trade - 00:00- $0.00m
- $5.19m
- $5.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -38.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.81 | 7.3 | 9.56 | 7.11 | 5.26 | n/a | n/a | -7.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Targeted Medical Pharma, Inc. is a medical nutrition company. The Company is engaged in developing amino acid based medical foods and other oral nutrition products for the long-term management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep, respiratory disorders, allergies and cognitive disorders. It manufactures eight amino acid based medical foods along with the dietary supplements, which include Grotrexa, AppTrim, Hypertensa Advanced and Clearwayz. Its Targeted Cellular Technology is a patented formulation that allows reduced concentrations of amino acids and other ingredients in the milligram range to stimulate the production of neurotransmitters to treat the nutritional deficiencies associated with certain diseases and conditions. The Company’s medical food brands include Theramine, Trepadone, Percura, GABAdone, Sentra PM, AppTrim-D and Sentra AM.
Directors
- Kerry Weems NEC (58)
- Marcus Charuvastra CEO
- Kim Giffoni EVP (64)
- Douglas Gintz CTO (49)
- Maurice DeWald IND (79)
- Thomas Wenkart IND (72)
- Last Annual
- December 31st, 2015
- Last Interim
- December 31st, 2015
- Incorporated
- October 4th, 2006
- Public Since
- September 10th, 2012
- No. of Employees
- 41
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 30,185,727
- Address
- 2980 Beverly Glen Circle, Suite 301, LOS ANGELES, 90077
- Web
- http://www.tmedpharma.com/
- Phone
- +1 3104749809
- Auditors
- Marcum LLP
Similar to TRGM
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 23:35 UTC, shares in Targeted Medical Pharma are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Targeted Medical Pharma last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Targeted Medical Pharma share price has underperformed the S&P500 Index by -99.07% over the past year.
There is no consensus recommendation for this security.
Find out moreTargeted Medical Pharma does not currently pay a dividend.
Targeted Medical Pharma does not currently pay a dividend.
Targeted Medical Pharma does not currently pay a dividend.
To buy shares in Targeted Medical Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Targeted Medical Pharma had a market capitalisation of $0.00m.
Here are the trading details for Targeted Medical Pharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TRGM
Based on an overall assessment of its quality, value and momentum Targeted Medical Pharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Targeted Medical Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -98.96%.
As of the last closing price of $0.00, shares in Targeted Medical Pharma were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Targeted Medical Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Targeted Medical Pharma's management team is headed by:
- Kerry Weems - NEC
- Marcus Charuvastra - CEO
- Kim Giffoni - EVP
- Douglas Gintz - CTO
- Maurice DeWald - IND
- Thomas Wenkart - IND